Rodney Badger, MD
Interventional Cardiology · Orem, UTNPI 1003874439
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,382 of the $10,628 with a category attached, or 78.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,304 and has fallen 79.8% since, to $466 in 2025.
Across 179 payments — averaging $59.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Merit Medical Systems Inc$2K
- Abiomed$1K
- Boston Scientific$851
- Inari Medical, Inc.$764
- Biotronik Inc.$669
- plus $3K from 22 others
What the payments were for
- Consulting fees$2,13420%
- Travel & lodging$430%
- Food & beverage$8,38279%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $2,332 |
| Merit Medical Systems Inc | 3 | $2,177 |
| Abiomed | 28 | $1,157 |
| Boston Scientific | 18 | $851 |
| Inari Medical, Inc. | 7 | $764 |
| Biotronik Inc. | 12 | $669 |
| Shockwave Medical, Inc | 8 | $429 |
| Abbott | 5 | $367 |
| Bard Peripheral Vascular, Inc. | 4 | $306 |
| Edwards Lifesciences | 3 | $292 |
| E.r. Squibb & Sons, L.L.C. | 6 | $202 |
| Cardiovascular Systems Inc. | 3 | $143 |
| AstraZeneca | 1 | $116 |
| Amgen | 2 | $109 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $103 |
| Merck | 4 | $70 |
| Novartis | 3 | $67 |
| Philips North America LLC | 1 | $66 |
| GSK | 3 | $62 |
| Penumbra, Inc. | 2 | $61 |
| Johnson & Johnson | 3 | $60 |
| Terumo Medical Corporation | 1 | $57 |
| Transit Scientific, LLC | 2 | $52 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Novo Nordisk | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Pfizer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,628 in reported general payments places this provider in the 65th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 13 | $10,366 |
| ClopidogrelClopidogrel Bisulfate | 93 | $804 |
| Atorvastatin Calcium | 26 | $245 |
| Lisinopril | 22 | $140 |
| Metoprolol Tartrate | 29 | $120 |
| Amlodipine Besylate | 26 | $85 |
| Rosuvastatin Calcium | 17 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $67 | $10,36613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 45 interventional cardiology providers in Utah.
Other interventional cardiology in Orem
- Richard GelbOrem$5K
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
- Sanjeev TrehanOgden$95K
- Stavros DrakosSalt Lake City$79K
- Tareq HarbOgden$27K
- Frederick WeltSalt Lake City$26K
- Jared CrisafiSt George$24K
- Scott HackingSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.